

TRANSLATION: Please note that the following is an English translation of the original Japanese version, prepared only for the convenience of shareholders residing outside Japan. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

December 5, 2018

To Our Shareholders

Christophe Weber
President and Representative Director
Takeda Pharmaceutical Company Limited
1-1, Doshomachi 4-chome
Chuo-ku, Osaka 540-8645, Japan

Notice of Resolutions at the Extraordinary General Meeting of Shareholders

Dear Shareholders:

We hereby report as follows on the matters reported on and the resolutions made at the Extraordinary General Meeting of Shareholders of the Company held today.

Matters resolved:

First Proposal: Delegation to the Board of Directors of the decision regarding offering terms for share issuance to implement the proposed acquisition of Shire
This item was approved as originally proposed.

Second Proposal: Election of Three (3) Directors who are not Audit and Supervisory Committee Members

As proposed, Ian Clark, Olivier Bohuon and Steven Gillis were each elected to the Takeda Board, conditional upon the Scheme of Arrangement in relation to the Acquisition (the “Scheme”) becoming effective with effect from the date which the Scheme becomes effective. The effective date of the Scheme is expected to be January 8, 2019.

Ian Clark, Olivier Bohuon and Steven Gillis will be External Directors defined in Article 2, item 15 of the Companies Act of Japan.

End of Document